Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 1
1961 2
1962 1
1965 1
1967 3
1968 1
1973 2
1974 2
1978 1
1980 3
1981 3
1982 3
1983 3
1985 4
1986 1
1987 1
1988 1
1989 2
1990 5
1991 5
1992 3
1993 1
1994 4
1995 3
1996 1
1997 1
1998 3
2000 1
2001 3
2002 4
2003 4
2004 2
2005 6
2006 8
2007 10
2008 9
2009 10
2010 11
2011 10
2012 16
2013 20
2014 16
2015 21
2016 23
2017 22
2018 26
2019 19
2020 24
2021 23
2022 33
2023 28
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

382 results

Results by year

Filters applied: . Clear all
Page 1
The Future of Atopic Dermatitis Treatment.
Lovell K, Patel N, Rao S, Strowd LC. Lovell K, et al. Adv Exp Med Biol. 2024;1447:227-244. doi: 10.1007/978-3-031-54513-9_19. Adv Exp Med Biol. 2024. PMID: 38724797 Review.
Topical Prescription Management.
Lovell K, Ackerson B, Thorpe R, Nicholas M. Lovell K, et al. Adv Exp Med Biol. 2024;1447:117-129. doi: 10.1007/978-3-031-54513-9_11. Adv Exp Med Biol. 2024. PMID: 38724789 Review.
Special Considerations of Atopic Dermatitis in Skin of Color.
Marcelletti A, Shan DM, Abdi W, Lovell K, Obeime I, McMichael A. Marcelletti A, et al. Among authors: lovell k. Adv Exp Med Biol. 2024;1447:45-57. doi: 10.1007/978-3-031-54513-9_5. Adv Exp Med Biol. 2024. PMID: 38724783 Review.
Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial.
Balevic SJ, Benjamin DK Jr, Powderly WG, Smith PB, Gonzalez D, McCarthy MW, Shaw LK, Lindsell CJ, Bozzette S, Williams D, Linas BP, Blamoun J, Javeri H, Hornik CP; ACTIV-1 IM Study Group. Balevic SJ, et al. JAMA Netw Open. 2024 Apr 1;7(4):e247615. doi: 10.1001/jamanetworkopen.2024.7615. JAMA Netw Open. 2024. PMID: 38662372 Free PMC article. Clinical Trial.
Development and evaluation of a de-escalation training intervention in adult acute and forensic units: the EDITION systematic review and feasibility trial.
Price O, Papastavrou Brooks C, Johnston I, McPherson P, Goodman H, Grundy A, Cree L, Motala Z, Robinson J, Doyle M, Stokes N, Armitage CJ, Barley E, Brooks H, Callaghan P, Carter LA, Davies LM, Drake RJ, Lovell K, Bee P. Price O, et al. Among authors: lovell k. Health Technol Assess. 2024 Jan;28(3):1-120. doi: 10.3310/FGGW6874. Health Technol Assess. 2024. PMID: 38343036 Free PMC article.
Behavioural activation to mitigate the psychological impacts of COVID-19 restrictions on older people in England and Wales (BASIL+): a pragmatic randomised controlled trial.
Gilbody S, Littlewood E, McMillan D, Atha L, Bailey D, Baird K, Brady S, Burke L, Chew-Graham CA, Coventry P, Crosland S, Fairhurst C, Henry A, Hollingsworth K, Newbronner E, Ryde E, Shearsmith L, Wang HI, Webster J, Woodhouse R, Clegg A, Dexter-Smith S, Gentry T, Hewitt C, Hill A, Lovell K, Sloan C, Traviss-Turner G, Pratt S, Ekers D; BASIL trials collective. Gilbody S, et al. Among authors: lovell k. Lancet Healthy Longev. 2024 Feb;5(2):e97-e107. doi: 10.1016/S2666-7568(23)00238-6. Lancet Healthy Longev. 2024. PMID: 38310902 Free PMC article. Clinical Trial.
382 results